Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Update

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totaling 11,149,487 shares, a drop of 17.6% from the December 15th total of 13,528,238 shares. Currently, 14.0% of the shares of the stock are short sold. Based on an average daily volume of 11,616,018 shares, the days-to-cover ratio is currently 1.0 days. Based on an average daily volume of 11,616,018 shares, the days-to-cover ratio is currently 1.0 days. Currently, 14.0% of the shares of the stock are short sold.

Institutional Trading of Aspire Biopharma

A number of institutional investors have recently bought and sold shares of the stock. Optivise Advisory Services LLC boosted its stake in Aspire Biopharma by 120.9% during the second quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock worth $63,000 after buying an additional 128,660 shares during the period. Jane Street Group LLC lifted its holdings in shares of Aspire Biopharma by 625.8% in the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after acquiring an additional 131,533 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in shares of Aspire Biopharma in the 3rd quarter worth about $28,000. Finally, Crewe Advisors LLC boosted its stake in shares of Aspire Biopharma by 100.0% during the 2nd quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock worth $169,000 after purchasing an additional 313,427 shares during the period. 19.17% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ASBP shares. Wall Street Zen raised shares of Aspire Biopharma to a “sell” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Aspire Biopharma Trading Down 9.0%

Shares of NASDAQ ASBP opened at $2.01 on Wednesday. Aspire Biopharma has a 12-month low of $1.65 and a 12-month high of $632.00. The firm’s 50-day moving average price is $3.93 and its 200-day moving average price is $11.61. The stock has a market capitalization of $5.41 million, a price-to-earnings ratio of -4.02 and a beta of 0.81.

Aspire Biopharma (NASDAQ:ASBP) last issued its quarterly earnings data on Friday, November 14th. The company reported ($1.60) earnings per share for the quarter. The business had revenue of $0.00 million during the quarter.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.